About Neocytogen
Founded in 2024, Neocytogen Therapeutics is a biotechnology company focusing on universal cell and gene therapy, committed to developing innovative therapies for malignant tumors and chronic diseases. The company's core technologies include universal CAR-X platform, iPSC platform, next generation oncolytic virus platform, and exosome technology platform. The founding team of Neocytogen is composed of senior scientists from the National University of Singapore and Nanyang Technological University. The company is headquartered in Singapore. Have built an integrated center of R&D and production in Singapore to support future technology translation and clinical applications, enabling us to become a global leader in universal cell therapy.
Our Advantages
Focus on universal product development
Specializing in universal cell and gene therapy, it has four core technology platforms covering different disease areas. The synergy between platforms is expected to foster new treatment methods.
Deep technical accumulation
The scientific team has more than a decade of technical experience in the field of cell and gene therapy, providing a solid foundation for the development and sustainable advancement of innovative products.
Full-chain technology layout
The core technology team covers the entire process from upstream design innovation to downstream large-scale production, bringing together many high-end talents and creating a complete chain from basic research to industrialization.
Research Centers
Global Layout, Collaborative Innovation
PBC Research Center
Our Team
An innovative team composed of international scientists and industry elites
Daniel Li, PhD
Scientific Founder, Executive Director, CSO
Yun Xia, PhD
Scientific Founder, Chief Scientist
Ms. Tina Tan
Co-Founder, Executive Vice President
Jules Zha, PhD
Co-founder，Director of R&D